1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Blackstone Bets On Pharma In First Japan Buy, But Why?

 
• By Ian Haydock

Major private equity group Blackstone buys into pharma for its first acquisition in Japan, but amid challenges in the sector, the attractions take some unraveling.

Business teamwork puzzle pieces.
Blackstone Makes First Japan Acquisition • Source: Shutterstsock

Funds under The Blackstone Group are buying the private specialty firm Ayumi Pharmaceutical, in a signal that the US private equity giant sees attractive returns down the road from what is its first controlling private investment in Japan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By Ian Haydock

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By Lisa Takagi

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Eisai Expands Dementia Ecosystem Via EcoNaviSta Acquisition

 
• By Lisa Takagi

Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.

Multiple Factors Behind Accelerating Private Equity Plays In Japan, APAC

 
• By Ian Haydock and Lisa Takagi

With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.

More from Focus On Asia

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.